Clinical trials: Carcinomas/Neoplasms
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Carcinoma
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small…
- Trial name
- NCT04363255
- Testing
- Etoposide Injection, Carboplatin Injection, Cisplatin injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Taizhou Hospital
Clear Cell Renal Cell Carcinoma
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential.
- Trial name
- PEP-C (NCT04053855)
- Testing
- Urinary sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Solid Tumor, Small Cell and Non-small Cell Lung Cancer
RAPA-201 Therapy of Solid Tumors
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of…
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity
- Trial name
- NCT05144698
- Testing
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Rapa Therapeutics LLC
HCC - Hepatocellular Carcinoma
Sarcopenia and Systemic Therapy in HCC
This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.
- Trial name
- Sarco HCC (NCT06805552)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Neoplasms, Hiv
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
This study evaluates whether the Potlako+ intervention of community education, clinical provider support, and patient navigation can improve access to cancer case for patients presenting with symptoms of cancer.
- Conditions
- Neoplasms, Hiv, Cervical Cancer, Breast Cancer
- Trial name
- Potlako+ (NCT04141449)
- Testing
- Potlako intervention, Enhanced care
- Where
- Botswana
- Volunteers
- 874 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Colorectal Neoplasms, Colonic Neoplasms
Study Evaluating EKB-569 in Advanced Colorectal Cancer
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer.
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00072748
- Testing
- EKB-569
- Volunteers
- 63 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Anaplastic Throid Carcinoma
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
- Trial name
- NCT06856278
- Testing
- NKG2D CAR-NK with PD-1 Antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Non-Small Cell Lung Cancer, Metastatic Lung Carcinoma
Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide and accounts for approximately 80% of all lung cancer cases.
- Trial name
- NCT07500285
- Testing
- Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor (Y-90 FAPI)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Breast Cancer, Ductal Carcinoma in Situ
Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen.
- Trial name
- NCT00886535
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Liver Cancer, Hepatocellular Carcinoma (HCC)
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post…
- Trial name
- NCT04933435
- Testing
- Quality of life questionnaires
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Duke University
Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and…
- Conditions
- Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07363408
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Lung Cancer, Non-Small Cell
NSCLC Burden of Illness Study
The aim of this observational study is to identify and quantify the humanistic and economic burden of illness of patients with complete resection (no residual disease) of stage IB-IIIA NSCLC in three European countries (France…
- Trial name
- LuCaBIS (NCT01772225)
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents…
- Trial name
- KaRAnaSa (NCT07227025)
- Testing
- Amivantamab, Olomorasib
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Epithelial Ovarian Cancer
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
This study is to determine the feasibility of postoperative platinum-based chemotherapy plus adjuvant and maintenance bevacizumab after neoadjuvant chemotherapy followed by interval surgery in patients with extensive stage IIIC…
- Trial name
- NCT02022917
- Testing
- Bevacizumab
- Where
- 5 sites in Taiwan
- Volunteers
- 22 people
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer
FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy
The investigators propose iRADIOMICS, a highly innovative and potentially clinical practice changing tool, which will allow for better management of patients undergoing immunotherapy.
- Trial name
- NCT04007068
- Testing
- FDG PET/CT
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC
- Trial name
- NCT04699968
- Testing
- SHR-1701，Famitinib, SHR-1701
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.